{"body":"<p>The 2020 HIV consolidated strategic information guidelines <em>(1)<\/em> recommend the percentage of people receiving ART with treatment-limiting toxicity as the priority indicator for monitoring ARV toxicity. Treatment-limiting toxicity is defined as a life-threatening illness, death, hospitalization, disability or a serious adverse drug reaction that results in drug discontinuation or substitution <em>(1).<\/em><\/p>&#13;\n&#13;\n<p>This indicator measures the prevalence of serious ARV drug toxicity among people receiving ART. Routine monitoring integrated into routine HIV patient monitoring systems will provide data on the clinical significance of serious toxicity and how this affects patient outcomes and attrition. Information on the prevalence of toxicity will inform national guidelines and efforts to prevent and limit ARV drug toxicity.<\/p>","title":"8.6.1 Routine monitoring for ARV toxicity","nid":628,"vid":2678,"created":1632394377,"changed":1632396027,"field_content_type":{"tid":1,"name":"Content","class":"content"}}